Clinical trials: Primary Immune Deficiency Disorders
Hereditary Angioedema
Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)
To assess the efficacy of recombinant human C1-esterase inhibitor in the management of HAE prodrome for preventing the progression from prodrome to an acute angioedema attacks.
- Trial name
- NCT06690047
- Testing
- Ruconest
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Bernstein Clinical Research Center
Hereditary Angioedema, HAE
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in participants with hereditary angioedema (HAE).
- Trial name
- OPuS-2 (NCT02303626)
- Testing
- BCX4161
- Where
- 40 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- BioCryst Pharmaceuticals
Pain
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
The primary aim of this study is to determine if chronic pain subjects on around-the-clock opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely transitioned on to buprenorphine…
- Trial name
- NCT01871285
- Testing
- Buprenorphine, Oxycodone, Morphine sulfate
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- BioDelivery Sciences International
Primary Immunodeficiency Diseases (PIDD)
Expanded Access to TAK-881 for People With Primary Immunodeficiency Diseases in the USA and Czech Republic
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. This study will provide access to TAK-881 for participants with PIDD who have completed study TAK-881-3002…
- Trial name
- NCT06955793
- Testing
- TAK-881, SC Investigational Needle Sets
- Sponsor
- Takeda
Refractory Viral Infections
Multivirus-specific Cytotoxic T Lymphocytes (mCTL)
PIDD represent an expanding group of genetic disorders that compromise immunity against bacteria, viruses, and fungi. The most severe forms of PIDD cause profound susceptibility to opportunistic infections due to impaired or…
- Trial name
- NCT02510404
- Testing
- mCTLs
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Catherine Bollard
THC, Cannabis
THC Crossover Study
This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from…
- Conditions
- THC, Cannabis, Cannabis Smoking, Cannabis Use, Unspecified
- Trial name
- TRDRP (NCT04429568)
- Testing
- Smoked Cannabis, Vaped Cannabis, Tobacco Cigarette
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Immune System Diseases
Retroviral Insertion Site Methodology Study
Adenosine deaminase (ADA) is an enzyme involved in the development and functioning of the immune system. Deficiency of ADA results in severe combined immunodeficiency (SCID), a fatal inherited immune disorder.
- Trial name
- NCT03311074
- Testing
- Strimvelis
- Sponsor
- Fondazione Telethon
HIV Infections
A Study of Patients Who Recently Have Been Infected With HIV
The purpose of this study is to find out if anti-HIV drugs, taken by patients who are newly infected with HIV, can make the level of HIV in the body too low to detect.
- Trial name
- NCT00006415
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acne Vulgaris, Allergic Rhinitis
MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use
The specific aim of this proposed pilot study is to compare two standardized processes (paper and electronic) to deliver a customized MedlinePlus health information prescription.
- Conditions
- Acne Vulgaris, Allergic Rhinitis, Anxiety, Asthma
- Trial name
- NCT01050465
- Testing
- health information prescription
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Ataxia-Telangiectasia (A-T)
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
This expanded access program provides investigational levacetylleucine to patients with Ataxia-Telangiectasia who are not eligible for clinical trials and have no satisfactory alternative therapies.
- Trial name
- NCT07380165
- Testing
- Levacetylleucine
- Sponsor
- IntraBio Inc
HIV Infections
Identifying Emergency Room Patients Who Have Recently Been Infected With HIV
The purpose of this study is to identify patients who have early HIV infection. Patients who have been infected with HIV recently may develop flu-like symptoms within 3 to 8 weeks.
- Trial name
- NCT00001130
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and…
- Trial name
- NCT01182675
- Testing
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Hereditary Angioedema (HAE)
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months.
- Trial name
- EMPOWER (NCT03845400)
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 168 people
- Sponsor
- Shire
Primary Immunodeficiency, Common Variable Immunodeficiency
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
Primary humoral immunodeficiency (PHID), such as common variable immunodefiency, are the most common symptomatic primary immunodeficiency in adults, in France.
- Conditions
- Primary Immunodeficiency, Common Variable Immunodeficiency, Igg Subclass Deficiency, Selective IgM Deficiency
- Trial name
- PREDDICHA (NCT06355323)
- Testing
- Blood test, chest CT scan
- Where
- France
- Volunteers
- 46 people
- Sponsor
- CHU de Reims
Primary Immunodeficiency
Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml
Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune related disorders both as immune-replacement and immune-modulating therapy.
- Trial name
- Nanogam (NCT01985373)
- Testing
- Intravenous immunoglobulin infusion
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Prothya Biosolutions
Hereditary Angioedema (HAE)
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.
- Trial name
- NCT05460325
- Testing
- Lanadelumab
- Where
- 4 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
Hiv
Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients
A Randomized, Double-Blind, Parallel-Group, Exploratory Clinical Study to Evaluate the Safety, Pharmacodynamic Effects, and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Treatment-Naive…
- Trial name
- NCT06560489
- Testing
- Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
Severe Combined Immunodeficiency, T Cell Lymphocytopenia
Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
The goal of the proposed research is to establish the validity of a newborn screening method for severe combined immunodeficiency (SCID).
- Trial name
- NCT00845416
- Where
- 2 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- University of California, San Francisco
HIV/AIDS and Infections
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART…
- Trial name
- RHIVIERA-02 (NCT05300035)
- Testing
- Recombinant human monoclonal antibody (bNAbs)
- Where
- 17 sites in France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Seropositivity
A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)
What is known: There are 1.2 million people in the US who meet the indications for PrEP; yet, disparities exist in uptake. For example, only 9% of Black and 16% of Latino individuals, compared to 65% of White individuals, have…
- Trial name
- MOST:PrEP (NCT06334341)
- Testing
- Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment
- Where
- United States
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System